Astellas Pharma Inc (ALPMF)
11.16
0.00 (0.00%)
USD |
OTCM |
Mar 28, 16:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 20.02B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -17.51% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | 1.836 |
Price to Book Value | 1.878 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | 0.2390 |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.5794 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 36.38% |
Profile
Astellas Pharma Inc is a drug manufacturing company that sells pharmaceutical products across the globe. The vast majority of the company's revenue is derived from Japanese markets, followed by the Americas. Royalty income makes up a small percentage of Astellas' overall sales. Its largest therapeutic area by sales composition is oncology, followed by urology and transplantation. The company uses mergers and acquisitions as part of its long-term growth strategy. Astellas enters into strategic partnerships and licensing agreements to strengthen its commercialization platforms. |
URL | http://www.astellas.com |
Investor Relations URL | N/A |
HQ State/Province | N/A |
Sector | Healthcare |
Industry | Drug Manufacturers - General |
Equity Style | Large Cap/Growth |
Next Earnings Release | N/A |
Last Earnings Release | N/A |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Mar. 28, 2024 |
Ratings
Profile
Astellas Pharma Inc is a drug manufacturing company that sells pharmaceutical products across the globe. The vast majority of the company's revenue is derived from Japanese markets, followed by the Americas. Royalty income makes up a small percentage of Astellas' overall sales. Its largest therapeutic area by sales composition is oncology, followed by urology and transplantation. The company uses mergers and acquisitions as part of its long-term growth strategy. Astellas enters into strategic partnerships and licensing agreements to strengthen its commercialization platforms. |
URL | http://www.astellas.com |
Investor Relations URL | N/A |
HQ State/Province | N/A |
Sector | Healthcare |
Industry | Drug Manufacturers - General |
Equity Style | Large Cap/Growth |
Next Earnings Release | N/A |
Last Earnings Release | N/A |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Mar. 28, 2024 |